---
document_datetime: 2026-01-13 10:55:35
document_pages: 2
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/mavenclad-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
document_name: mavenclad-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 1.3330796
conversion_datetime: 2026-01-14 08:26:33.01251
docling_version:
  docling-serve: 1.10.0
  docling-jobkit: 1.8.1
  docling: 2.68.0
  docling-core: 2.59.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Mavenclad

Procedural steps taken and scientific information after the authorisation*

*Due to the Agency`s update of its procedure management systems, an additional document, reflecting the historical lifecycle may be available in the 'Assessment history' section. For the complete product lifecycle procedures, you may need to also refer to EPAR - Procedural steps taken and scientific information after authorisation (archive) .

| Application number   | Scope                                     | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary   |
|----------------------|-------------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|-----------|
| Variation type IB /  | C.I.3 Change(s) in the Summary of Product | 10/01/2026                          |                                             | SmPC, Annex                      |           |

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

| EMA/VR/0000316384                     | Characteristics, Labelling or Package Leaflet of human medicinal products intended to implement the outcome of a procedure concerning PSUR or PASS, or the outcome of the assessment done by the competent authority under Articles 45 or 46 of Regulation 1901/2006 - C.I.3.z Other variation - Accepted C.I.3.z - to update sections 4.4 and 4.6 of the SmPC, section D of Annex II to implement the outcome of PSUR procedure EMEA/H/C/PSUSA/00010634/202407 and to propose updated wording in section 2 of the Package Leaflet to comply to the same outcome. The RMP has been updated accordingly.   |            |     | II and PL   |
|---------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|-------------|
| Variation type II / EMA/VR/0000290090 | B.II.c.1 Change in the specification parameters and/or limits of an excipient - B.II.c.1.d Change outside the approved specifications limits range - Accepted                                                                                                                                                                                                                                                                                                                                                                                                                                             | 16/10/2025 | N/A |             |
| Variation type IA / EMA/VR/0000272100 | B.III.1.a European Pharmacopoeial Certificate of Suitability to the relevant Ph. Eur. Monograph - B.III.1.a.2 Updated certificate from an already approved manufacturer - Accepted                                                                                                                                                                                                                                                                                                                                                                                                                        | 14/05/2025 | N/A |             |